Citations

Clear

2368 citation(s) found for "Su, Jack".

0560 Associations of Late Midlife Sleep-Disordered Breathing with Late-Life Brain Amyloid Deposition
Wu, Mark, Lutsey, Pamela, Jack, Clifford, Yaffe, Kristine, Zipunnikov, Vadim, Wong, Dean, Chand, Ganesh, Bubu, Omonigho, Redline, Susan, Lucey, Brendan, Sharrett, A Richey, Gottesman, Rebecca, Spira, Adam, Jiang, Kening , Lutsey, Pamela L. , Jack, Clifford, Yaffe, Kristine , Zipunnikov, Vadim , Chand, Ganesh B. , Bubu, Omonigho M. , Redline, Susan , Lucey, Brendan P. , Sharrett, A. Richey, Gottesman, Rebecca

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A249-A249

10.1093/sleep/zsag091.0559 Get It

Abstract Introduction Sleep-disordered breathing (SDB) is a potentially modifiable risk factor for the prevention of dementia, of which Alzheimer’s disease (AD) is the most common cause. However, there is a lack of longitudinal evidence relating SDB to AD pathology >20 years later. We examined the association between late-midlife SDB and late-life brain β-amyloid (Aβ) deposition—a hallmark of AD—assessed approximately 23 years later. Methods The Atherosclerosis Risk in Communities (ARIC) Study is an ongoing prospective cohort study initiated in 1987. Participants at two ARIC sites (Washington County, Maryland; Minneapolis, Minnesota) with primarily White participants also completed polysomnography (PSG) in the Sleep Heart Health Study (SHHS) in 1995-98. SDB measures included apnea-hypopnea index (AHI; number of apneas + hypopneas with ≥3% oxygen desaturation/hour of sleep), arousal index, and percentage of total sleep time in apnea, in hypopnea, and with oxygen saturation < 90%. A subset of participants completed florbetapir positron emission tomography (PET) scans through several ARIC ancillary studies (2011-2025 including the ARIC Sleep-PET study). We defined Aβ deposition as a global standardized uptake value ratio (SUVR) >1.2 (vs. SUVR ≤1.2). We used Poisson regression with robust standard errors to estimate relative risk (RR) of Aβ deposition by SDB, adjusting for demographics and vascular risk factors, and applied inverse probability attrition weighting to account for selective drop-out. Results Among 186 dementia-free participants (mean age=59 years at PSG and 82 years at PET scan, 58% female, 98% White), every 10% increase in total sleep time in hypopnea was associated with higher risk of Aβ deposition (RR=1.40, 95% confidence interval [CI]: 1.03, 1.91). When compared to no SDB (AHI < 5), moderate to severe SDB (AHI ≥15) was associated with elevated Aβ deposition (RR=2.36, 95% CI: 1.22, 4.57); mild SDB (AHI 5 to < 15) was not (RR=1.05, 95% CI: 0.53, 2.07). Conclusion SDB in late midlife was associated with greater risk of Aβ deposition approximately 23 years later. SDB may play a role in the early stages of AD pathogenesis. Future longitudinal studies are needed to optimize strategies for screening and treating SDB for dementia prevention. Support (if any) Supported in part by RF1AG050745.
Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change
Burkett, Brian J. , Wiste, Heather J. , Johnson, D H, Boeve, Bradley F., Kantarci, Kejal, Petersen, Ronald C., Knopman, David S., Vemuri, Prashanthi, Graff‐Radford, Jonathan, Lowe, Val, Cogswell, Petrice M., Pillai, Jay, Schwarz, Christopher G., Murray, Melissa E., Dickson, Dennis W., Jack, Clifford R., Pillai, Jay J. , Burkett, Brian , Pillai, Jay J , Boeve, Bradley F. , Kantarci, Kejal , Petersen, Ronald C. , Knopman, David S. , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Lowe, Val J. , Cogswell, Petrice M. , Schwarz, Christopher G. , Nguyen, Aivi T. , Murray, Melissa E. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | May 7, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71449 | PMID 42092343 Get It

Abstract INTRODUCTION Alzheimer's disease neuropathologic change (ADNC) classification identifies not/low and intermediate/high levels of neuropathology. Our goal was to assess how frequently a positive amyloid positron emission tomography (PET) scan indicates not/low ADNC and whether this autopsy finding can occur >10 years after a positive amyloid PET. METHODS Participants with positive amyloid PET scans were categorized by levels of ADNC at autopsy, grouped by time from initial positive amyloid PET to time of death (<5 years, 5 to <10 years, or 10+ years). RESULTS Among those with a positive amyloid PET scan, the majority had intermediate/high ADNC at autopsy (234/259, 90%). In the group with 10+ years between a positive amyloid PET and death ( n = 39) not/low ADNC occurred in 3/39 (8%). DISCUSSION Not/low ADNC is uncommon among those with positive amyloid PET scans. After 10+ years, it is possible but rare for a positive amyloid PET scan to represent an indolent state of neuropathology.
Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia
Shrestha, Srishti , Zhu, Xiaoqian , Windham, B Gwen, Sullivan, Kevin J, Palta, Priya, Gottesman, Rebecca F, Tracy, Russell P, Jack, Clifford R, Cogswell, Petrice M, Vemuri, Prashanthi, Seshadri, Sudha, Mosley, Thomas H, Griswold, Michael E, Fornage, Myriam, Windham, B. Gwen , Sullivan, Kevin, Gottesman, Rebecca F. , Tracy, Russell P. , Jack, Clifford R. , Cogswell, Petrice M. , Vemuri, Prashanthi , Seshadri, Sudha , Mosley, Thomas H. , Griswold, Michael , Fornage, Myriam

Mayo Clinic

Alzheimer's & Dementia | May 7, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71422 | PMID 42092335 Get It

Abstract INTRODUCTION Prospective studies of blood‐based biomarkers reflecting pathogenic processes, other than Alzheimer‐specific pathologies, that contribute to dementia in diverse cohorts are lacking. METHODS We jointly fitted linear mixed‐effect models and proportional hazards models to examine associations of midlife glial fibrillary acidic protein (GFAP), chitinase‐3‐like protein 1 (YKL‐40), soluble cluster of differentiation‐14 (sCD14), neurofilament light chain (NfL), total tau (t‐tau), and ubiquitin C‐terminal hydrolase L1 (UCHL1) levels in serum (collected in 1993 to 1995) with cognitive decline and incident dementia (ascertained over 29 years through 2022) in the community‐based Atherosclerosis Risk in Communities Study. sCD14 and YKL‐40 were measured in 3082 participants and the other four biomarkers in 1766 participants. RESULTS Higher serum GFAP, YKL‐40, sCD14, and NfL were associated with faster cognitive decline and elevated dementia rate (e.g., 1 standard deviation [SD] higher log‐base2 YKL‐40 was associated with −0.11SD faster 25‐year cognitive decline (95% confidence interval [CI]: −0.15,−0.07) and 45% higher dementia hazard (hazard ratio [HR]: 1.45 [95% CI: 1.25, 1.68]). Higher t‐tau and UCHL1 were also associated with faster cognitive decline. DISCUSSION Midlife blood biomarkers reflecting glial and neuronal dysfunction and neuroinflammation are associated with early cognitive impairment.
Clinical Characteristics and Outcomes of Cytomegalovirus DNAemia in Non-HIV-Infected and Non-Transplant Patients: A Propensity Score-Matched Analysis
Salter, Ixchel, Corbisiero, Michaele-Francesco, Chiu, Chia‐Yu , Shapiro, Leland , Razonable, Raymund R., Henao-Martínez, Andrés F., Chastain, Daniel B , Chiu, Chia-Yu , Shapiro, Leland , Henao-Martínez, Andrés F , Salter, Ixchel T, Montoya, José G. , Razonable, Raymund R.

Mayo Clinic

Pathogens | May 1, 2026 | Volume: 15 | Issue: 5 | Pages: 492

10.3390/pathogens15050492 | PMID 42198618 Get It

Cytomegalovirus (CMV) establishes lifelong latency following primary infection and can reactivate to cause severe illness in immunocompromised hosts. CMV DNAemia in non-HIV-infected, non-solid organ/bone marrow transplant (NHNT) hosts is poorly characterized, with limited clinical insights. We aim to describe the clinical presentation, prognostic indicators, and outcomes of CMV DNAemia among NHNT patients. We used the TriNetX international patient database to identify adult patients diagnosed with CMV DNAemia from 2016 until March 2023. We evaluated hospitalization, intensive care unit (ICU) level care, and all-cause mortality at 30 days and 1 year. We also completed a post-propensity score analysis comparing clinical characteristics of survivors versus non-survivors at 90 days. We identified 1123 NHNT patients with CMV DNAemia, most of whom had neoplasms (63%). Venous thromboembolism occurred in 31% of the population. The 30-day hospitalization and all-cause mortality rates were 35% and 14%, respectively. After propensity score matching and Bonferroni correction, weakness, purpura, acute respiratory failure, malnutrition, encephalopathy, and hypotension were associated with increased 90-day all-cause mortality. NHNT patients with CMV DNAemia carry a substantial morbidity and all-cause mortality. Further studies are warranted to clarify whether CMV DNAemia is a causative factor or an incidental finding in this population.
MedSimAI: Simulation and Formative Feedback Generation to Enhance Deliberate Practice in Medical Education
Hicke, Yann , Geathers, Jadon , Vu, Kellen Vo , Sewell, Justin L. , Cardie, Claire, Talwalkar, Jaideep S. , Shung, Dennis , Jack, A. Gilbert , Preston, Mackenzi , Kizilcec, René F. , Cardie, Claire , Cornes, Susannah

Mayo Clinic

Proceedings of the LAK26: 16th International Learning Analytics and Knowledge Conference | April 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: 415-424

10.1145/3785022.3785092 Get It

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data
Goel, Utkarsh , Dragomirescu, Catalin , Zanwar, Saurabh , Cassano, Rafaella Cassano, Cicero, Kara I. , Cowan, Andrew J., Banerjee, Rahul, Anwer, Faiz , Khouri, Jack , Cowan, Andrew J , Anwer, Faiz , Cowan, Andrew J. , Banerjee, Rahul , Dima, Danai

Mayo Clinic

British Journal of Haematology | April 23, 2026 | Volume: 208 | Issue: 6 | Pages: 2134-2142

10.1111/bjh.70490 | PMID 42023513 Get It

Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less effective front‐line therapy. In this study, we combined data from three Center for International Blood and Marrow Transplant Research studies (MM18‐02, MM19‐01 and MM20‐03). We included patients who received front‐line AHSCT between 2008 and 2018 and had progression <12 (FHR12, n = 465), <18 (FHR18, n = 672) or <24 months (FHR24, n = 853) after AHSCT. We classified induction therapy as standard lenalidomide‐containing triplets (bortezomib, lenalidomide, dexamethasone [VRD]/carfilzomib, lenalidomide, dexamethasone [KRD]) versus other (bortezomib, thalidomide, dexamethasone [VTD]/bortezomib, cyclophosphamide, dexamethasone [VCD]/bortezomib, dexamethasone [VD]/lenalidomide, dexamethasone [RD]) and studied the impact of front‐line therapy on post‐FHR overall survival (OS). In the FHR12 cohort (follow‐up 48 months), the OS after VRD/KRD ( n = 238) was 21 versus 17 months with other regimens ( n = 227, hazard ratio [HR] = 1.2, 95% confidence interval [CI]: 0.6–1.06). In a multivariable model, the HR for OS was 0.94 (95% CI: 0.7–1.3, p = 0.69) for VRD/KRD versus other regimens. There was no significant interaction between type of first‐line (1L) therapy and time from 1L AHSCT to first relapse in predicting OS. Similar results were seen for FHR18 and FHR24. FHRMM remains a negative prognostic factor irrespective of front‐line therapy and warrants consideration of T‐cell engagers' second‐line therapy.
Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup
Grill, Joshua D., Salloway, Stephen, Atri, Alireza, Cogswell, Petrice M., Benzinger, Tammie L. S., Iwatsubo, Takeshi, Greenberg, Steven M., Carrillo, Maria C., Jack, Clifford R., Sperling, Reisa A., Carrillo, María C. , Etten, Ellis S. van , Mahinrad, Simin , Grill, Joshua D. , Salloway, Stephen , Atri, Alireza , Cogswell, Petrice M. , Benzinger, Tammie L.S. , Iwatsubo, Takeshi , Iadecola, Costantino , Lemere, Cynthia Ann , Nicoll, James A. R. , Greenberg, Steven M. , Jack, Clifford R. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | April 22, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71361 | PMID 42015334 Get It

Abstract In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid‐related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. Since then, anti‐amyloid immunotherapies have received regulatory approval for AD treatment and are beginning to enter clinical practice, underscoring the importance of informing healthcare providers, researchers, and patients about ARIA's implications in real‐world settings. In response, the Alzheimer's Association convened a new workgroup to review current knowledge of ARIA, including underlying mechanisms, clinical presentations, associated risk factors, mitigation strategies, radiologic detection methods, patients’ perspectives in treatment decision‐making, and outstanding challenges. Here, we outline key insights from this workgroup, highlighting that effective ARIA detection and monitoring in clinical practice requires adherence to robust protocols to mitigate risks and enhance patient safety. Limited availability of clinical and pathologic data on predictors of symptomatic and severe ARIA underscores the importance of continued real‐world data collection.
Default mode network failure across the Alzheimer’s disease spectrum
Corriveau‐Lecavalier, Nick , Dicks, Ellen , Martin, Peter R. , Wiste, Heather J. , Gunter, Jeffrey L. , Kamykowski, Michael G. , Senjem, Matthew L, Schwarz, Christopher G. , Botha, Hugo , Graff‐Radford, Jonathan , Machulda, Mary M, Fields, Julie A. , Lowe, Val J, Petersen, Ronald C, Boeve, Brad , Knopman, David S. , Jack, Clifford R , Jones, David T , Schwarz, Christopher G , Botha, Hugo , Corriveau-Lecavalier, Nick , Senjem, Matthew L. , Machulda, Mary M. , Boeve, Bradley F. , Lowe, Val J. , Knopman, David S. , Petersen, Ronald C. , Jack, Clifford R. , Jones, David T.

Mayo Clinic

Brain | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag146 | PMID 42019008 Get It

Abstract Alzheimer’s disease (AD) emerges from multi-scale interactions between molecular pathology and disruptions in large-scale brain network dynamics. Understanding how these processes co-evolve and relate to disease stages is essential for advancing complex systems models of aging and AD, and for developing system-informed interventions. However, progress has been limited by a lack of large-scale longitudinal data. To address this, we examined the longitudinal relationship between subsystems of the default mode network (DMN) (posterior DMN, ventral DMN, anterior dorsal DMN) using task-free functional MRI (fMRI) and amyloid positron emission tomography (PET) imaging in a large longitudinal cohort spanning the clinico-biological spectrum of AD (n = 1,451; 2,763 time points) using mixed-effect models. We also assessed whether patterns of DMN connectivity predicted conversion to amyloid positivity, mild cognitive impairment (MCI), and dementia using Cox proportional hazards models. Our findings reveal a dynamic interplay between amyloid accumulation and connectivity within and between DMN subsystems, with both hyper- and hypoconnectivity emerging across DMN subsystems in association with increasing amyloid burden. Importantly, survival models showed that DMN connectivity patterns predicted conversion to critical stages of the disease, including not only conversion to MCI and dementia, but also conversion to amyloid positivity in otherwise clinically unimpaired individuals who were amyloid negative at baseline. These associations were independent of age, APOE4 status, sex, education, and in-scanner motion. These results support a model in which breakdowns in tightly regulated feedback loops governing DMN physiology represent a core systems-level pathophysiology of AD. Notably, this functional dyshomeostasis precedes detectable amyloidosis on imaging. Future studies should focus on the development of robust biomarkers of brain function that can be applied at the individual level, which could in turn help support the development of therapeutic approaches targeting system-level pathophysiology.
Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025)
Kanoria, Shaveta , Miller, Melanie J., Aisen, Paul S., Beckett, Laurel A., Green, Robert C., Harvey, Danielle J., Jack, Clifford R., Jagust, William, Lee, Edward B., Nho, Kwangsik, Nosheny, Rachel, Okonkwo, Ozioma C., Perrin, Richard J., Petersen, Ronald C., Saykin, Andrew J., Shaw, Leslie M., Toga, Arthur W., Tosun, Duygu, Landau, Susan M., Weiner, Michael W. , Initiative, for the Alzheimer's Disease Neuroimaging, Harvey, Danielle , Weiner, Michael W , Harvey, Danielle J , Veitch, Dallas P. , Miller, Melanie J. , Aisen, Paul , Beckett, Laurel , Green, Robert C. , Jack, Clifford R. , Jagust, William J. , Lee, Edward B. , Nho, Kwangsik T. , Nosheny, Rachel, Perrin, Richard J. , Petersen, Ronald C. , Mindt, Mónica Rivera , Saykin, Andrew J. , Shaw, Leslie M. , Toga, Arthur W. , Landau, Susan , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | April 16, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71353 | PMID 41988903 Get It

Abstract Alzheimer's disease (AD) continues to pose a major public health challenge. Since its launch in 2004, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has played a pivotal role in advancing the field by providing a comprehensive, open‐access, longitudinal dataset that integrates neuroimaging, biomarker, genetic, and clinical data related to AD. We used standard literature search methods to identify ∼1830 publications from 2023 to mid‐2025 that used ADNI data or samples. This review highlights key ADNI studies with direct clinical applications. We describe how these have impacted the development and validation of plasma biomarkers, improved clinical trials, assessed AD therapies, and developed methods for diagnosis and prediction using clinical, fluid, and imaging biomarkers. These contributions are underlain by an improved understanding of biological mechanisms of disease progression in AD and highlight ADNI's central role in advancing translational research and accelerating progress toward more effective, individualized care for patients with AD.
Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies
Ferreira, Daniel, Chmiela, Tomasz , Eriksdotter, Maria, Jack, Clifford R., Marseglia, Anna , Mecocci, Patrizia , Nordberg, Agneta, Westman, Eric, Marseglia, Anna , Mecocci, Patrizia , Chmiela, Tomasz , Ferreira, Daniel , Eriksdotter, Maria , Jack, Clifford R. , Kalpouzos, Grégoria , Nordberg, Agneta , Religa, Dorota , Westman, Eric

Mayo Clinic

Journal of Internal Medicine | April 16, 2026 | Volume: 299 | Issue: 6 | Pages: 694-710

10.1111/joim.70096 | PMID 41988825 Get It

Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms. The most common co‐pathologies in people with AD are alpha‐synucleinopathy, vascular brain injury and transactive response DNA‐binding protein of 43 kDa‐related pathology. Neuroinflammation, iron accumulation, cholinergic dysfunction and cellular senescence are recognized pathobiological processes beyond Aβ‐ and tau‐related pathology. However, the exact mechanisms by which these co‐pathologies and pathobiological processes contribute to the neurodegeneration and clinical symptoms in people with AD remain unclear. The individual combination of these co‐pathologies and pathobiological processes increases phenotypical heterogeneity in people with AD. This highlights the unmet need to advance their current understanding, and the field strives to develop accurate biomarkers for personalized assessment and investigation. Elucidating this biologic‐clinical complexity and heterogeneity is crucial for increasing our current understanding of AD, with implications for diagnosis, prognosis and therapeutics.